Reference replicated designs [Regulatives / Guidelines]

posted by rajasekharkakarla – India, 2019-09-20 08:35 (1679 d 09:52 ago) – Posting: # 20628
Views: 1,791

Dear All,

As per FDA guidelines "We recommend that if the predose value is greater than 5 percent of Cmax, you drop the subject from all BE study evaluations".

Is it applicable for fully replicated designs also, if i got greater than 5% Cmax in period 4 whether i need to exclude the subject from entire study or can we use available data for Swr calculations if subject completed two reference treatment periods.

Thanks&Regards,
Rajasekhar

Complete thread:

UA Flag
Activity
 Admin contact
22,993 posts in 4,828 threads, 1,651 registered users;
108 visitors (0 registered, 108 guests [including 3 identified bots]).
Forum time: 18:27 CEST (Europe/Vienna)

Never never never never use Excel.
Not even for calculation of arithmetic means.    Martin Wolfsegger

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5